Beyond the Guidelines: Biomarker Assessment and Targeted Therapy for Metastatic Colorectal Cancer (Video Program)

Beyond the Guidelines: Biomarker Assessment and Targeted Therapy for Metastatic Colorectal Cancer is organized by Research To Practice (RTP).

Release Date: November 2020
Expiration Date: November 2021

Accreditation:
Video Program: 
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.5 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity.

Learning Objectives:
• Coordinate comprehensive biomarker analysis for patients diagnosed with metastatic colorectal cancer (mCRC), and use the results to guide evidence-based care.
• Develop a long-term care plan for individuals with mCRC, considering patient and disease characteristics, including biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
• Appreciate published research data documenting the efficacy of the BRAF inhibitor encorafenib in combination with the EGFR inhibitor cetuximab for patients with relapsed/refractory mCRC and a BRAF V600E mutation in order to optimally incorporate this therapeutic strategy into current clinical algorithms.
• Appraise the FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab/ipilimumab for patients with microsatellite instability-high or mismatch repair-deficient mCRC, and appropriately integrate these agents into current nonresearch treatment algorithms.
• Educate patients with mCRC about side effects associated with approved and investigational targeted agents and immunotherapies, and develop a plan to optimally recognize and manage these toxicities.